艾迪注射液配合肝动脉化疗及栓塞治疗原发性肝癌临床疗效观察

 目的 观察艾迪注射液配合肝动脉化疗及栓塞治疗原发性肝癌的疗效。方法 63例原发性肝癌患者随机分为二组，治疗组(33例)为艾迪注射液配合肝动脉化疗及栓塞疗法，对照组(30例)为单纯肝动脉化疗及栓塞。结果 治疗组与对照组的近期客观疗效分别为60．6％和53．3％，临床症状改善率分别为72．7％和33．3％，生存质量改善率分别为54．5％和30．0％。经统计学处理，两组在临床症状及生存质量改善方面差异有显著意义，P<0．05。结论 艾迪注射液配合肝动脉化疗及栓塞治疗原发性肝癌，有助于临床症状的改善和生存质量的提高。

Clinical Study of Aidi Injection Combined with Transcather Hepatic Arterial Chemoembolization in the Treatment of Primary Liver Cancer

Objective To investigate the therapeutic effect of Aidi injection combined with transcather hepatic arterial chemoembolization in treatment for primary liver cancer. Methods Sixty-three cases with primary liver cancer were randomly divided into two groups. The treated group (n=33) received Aidi injection combined with transcather hepatic arterial chemoembolization, and the control group (n=30) were treated with transcather hepatic arterial chemoembolization alone. Results The response rates in the treated group and control group were 60.6% and 53.3% respectively .The remission of symptoms were 72.7% and 33.3% respectively .The improvement of life quantity were 54.5% and 30.3% respectively. In the clinical symptoms and the quality of life, there were significant difference between the two groups, P< 0.05. Conclusion The treatment of Aidi injection combined with transcather hepatic arterial chemoembolization was helpful to improve the clinical symptoms and the quality of life for patients with primary liver cancer.